Edetic Acid

Edetic Acid

SCHEMBL705313

O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].[NaH]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.93
EYA2 O00167 1/20 0.93
APP P05067 1/20 0.93
ACE P12821 1/20 0.93
BLM P54132 2/20 0.88
PMP22 Q01453 2/20 0.88
TSHR P16473 2/20 0.88
KDM4E B2RXH2 2/20 0.88
ALOX15 P16050 2/20 0.88
LMNA P02545 1/20 0.88
CHRM2 P08172 1/20 0.88
ADRA2A P08913 1/20 0.88
DRD1 P21728 1/20 0.88
SLC6A2 P23975 1/20 0.88
SLC6A4 P31645 1/20 0.88
CYP2C19 P33261 1/20 0.88
ADRA1A P35348 1/20 0.88
DRD3 P35462 1/20 0.88
SLC6A3 Q01959 1/20 0.88
HRH3 Q9Y5N1 1/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Edetic Acid SCHEMBL43566 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL5514144 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL905 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL8350628 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL5325092 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL33500 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL17386368 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL7698156 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL1420837 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL42426 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023239972-A1 MINOXIDIL ADJUVANT THERAPIES Jupiter Wellness, Inc. (US) 2023-12-14 WO disclosed
US-20230364027-A1 Compositions Comprising (Bio)-Alkanediols with Antimicrobials for Product Protection AG, SYMRISE (US) 2023-11-16 US disclosed
US-20230293410-A1 Compositions Comprising Lipophilic Compounds and One or More (Bio)-Alkanediols SYMRISE AG (DE) 2023-09-21 US disclosed
EP-4152930-A2 BIOBASED ALKYL GLYCERYL ETHERS AND METHODS OF MAKING AND USING THE SAME Inolex Investment Corporation (US) 2023-03-29 EP disclosed
WO-2021237207-A2 BIOBASED ALKYL GLYCERYL ETHERS AND METHODS OF MAKING AND USING THE SAME INOLEX INVESTMENT CORPORATION (US) 2021-11-25 WO disclosed
CN-107519040-B Clear suspended personal care cleansing compositions 强生消费者公司 2021-10-08 CN disclosed
CN-107072907-B Compositions comprising zwitterionic ester aminoalkanoates 强生消费者公司 2020-12-29 CN disclosed
WO-2018236806-A1 TOPICAL COMPOSITIONS AND METHODS OF USING THE SAME NOVAN, INC. (US) 2018-12-27 WO disclosed
EP-3139891-A1 COMPOSITIONS COMPRISING SYNTHETIC WAXES Micro Powders Inc. (US) 2017-03-15 EP disclosed
WO-2015171986-A1 COMPOSITIONS COMPRISING SYNTHETIC WAXES Micro Powders, Inc. (US) 2015-11-12 WO disclosed
US-7008917-B2 Cleaning composition in a concentrated form comprising tetrahydrofurfuryl alcohol THE KNOCKOUT GROUP, INC. (US) 2006-03-07 US disclosed
US-20050274399-A1 Method of fomulating a cleaning composition in a concentrated form CHARLESTON HOLDINGS, LLC 2005-12-15 US disclosed
US-20050277572-A1 CLEANING COMPOSITION IN A CONCENTRATED FORM COMPRISING TETRAHYDROFURFURYL ALCOHOL CHARLESTON HOLDINGS, LLC 2005-12-15 US disclosed
US-20050277564-A1 Method of formulating a cleaning composition for use in cleaning surfaces CHARLESTON HOLDINGS, LLC 2005-12-15 US disclosed
EP-0915693-A1 AN OIL-IN-WATER EMULSION FOR USE ON HUMAN SKIN FOR CLEANSING, PRESERVING OR IMPROVING THE CONDITION OF THE SKIN Plum Kemi Produktion A/S (DK) 1999-05-19 EP disclosed
EP-0875620-A1 Process for dyeing melamine fibers and melamine fibers so dyed BASF CORPORATION (US) 1998-11-04 EP disclosed
EP-0874080-A1 Dyeing articles composed of melamine fiber and cellulose fiber BASF CORPORATION (US) 1998-10-28 EP disclosed
EP-0874079-A1 Improved comfort melamine fabrics and process for making them BASF CORPORATION (US) 1998-10-28 EP disclosed
EP-0874081-A1 Dyeing articles composed of melamine and aramid fibers BASF CORPORATION (US) 1998-10-28 EP disclosed
WO-1998005294-A1 AN OIL-IN-WATER EMULSION FOR USE ON HUMAN SKIN FOR CLEANSING, PRESERVING OR IMPROVING THE CONDITION OF THE SKIN PLUM KEMI PRODUKTION A/S (DK) 1998-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364027-A1 Compositions Comprising (Bio)-Alkanediols with Antimicrobials for Product Protection AKR7A2, HAAO, ABHD5 TDP1 3764/4885EYA2 1341/4885APP 259/4885
US-20230293410-A1 Compositions Comprising Lipophilic Compounds and One or More (Bio)-Alkanediols TRPA1, CUTA, OR51E2 TDP1 2031/4885EYA2 1011/4885APP 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.